^
    1d
    MP0533-CP101: Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=249, Active, not recruiting, Molecular Partners AG | Recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> May 2027 | Trial primary completion date: Dec 2027 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    Venclexta (venetoclax) • azacitidine • Gazyva (obinutuzumab) • MP0533
    9d
    TP53 deficiency in AML induces resistance to T-cell engagers through an immunosuppressive secretome. (PubMed, Leukemia)
    Cytotoxicity against TP53-deleted (DEL) primary AML cells and TP53-knockdown (KD) AML cell lines was reduced in co-cultures with T cells stimulated with the BiTE molecule AMG 330 (CD3×CD33)...RNA sequencing of T cells co-cultured with TP53 KD cells uncovered a transcriptional shift toward a senescent cell cycle profile. Our data collectively identify the immunosuppressive secretome of TP53-deficient AML as a key barrier to T-cell-engaging immunotherapies, underscoring an unmet clinical need for strategies able to restore T-cell function in TP53 KD AML.
    Journal • IO biomarker
    |
    TP53 (Tumor protein P53) • CD33 (CD33 Molecule) • TGFB1 (Transforming Growth Factor Beta 1)
    |
    TP53 mutation
    |
    eluvixtamab (AMG 330)
    12d
    A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies (clinicaltrials.gov)
    P1, N=9, Recruiting, Zelluna Immunotherapy AS
    New P1 trial
    |
    MAGEA4 (Melanoma antigen family A, 4)
    |
    cyclophosphamide • fludarabine IV
    18d
    Autologous T Cell Antigen Coupler Targeting HER2 (TAC01-HER2) in Advanced or Metastatic Solid Tumors. (PubMed, Ann Oncol)
    TAC01-HER2 showed manageable toxicity and early efficacy for patients with HER2-positive gastric, GEJ or esophageal adenocarcinoma who have undergone extensive previous treatments. These results suggest that TAC may offer a promising approach to control T cell activity through cellular therapy.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    TAC01-HER2 (Auto)
    19d
    DERIVe: DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab (clinicaltrials.gov)
    P2, N=43, Active, not recruiting, Annick Desjardins, MD | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    MGMT (6-O-methylguanine-DNA methyltransferase) • CCL3 (C-C Motif Chemokine Ligand 3)
    |
    temozolomide • varlilumab (CDX 1127)
    22d
    Novel bispecific T-cell engagers overcoming acquired EGFR resistance. (PubMed, MAbs)
    However, intrinsic and acquired resistance to EGFR-targeted antibody therapies such as cetuximab remains a major limitation to achieving broad and durable treatment responses...Anti-tumor activity was additionally demonstrated in an EGFR-expressing CT-26 syngeneic tumor model in vivo. Collectively, these findings define a promising therapeutic strategy to overcome resistance to current EGFR-targeted therapies and provide a strong rationale for the development of next-generation T-cell - redirecting therapies in patients with EGFR-positive malignancies.
    Journal
    |
    EGFR (Epidermal growth factor receptor) • KRAS (KRAS proto-oncogene GTPase)
    |
    EGFR mutation • EGFR expression • EGFR wild-type • KRAS wild-type • RAS wild-type • EGFR positive
    |
    Erbitux (cetuximab)
    1m
    Ion-Channel-Mediated Drug Repurposing Opportunities Validated by Single-Cell Perturbation in Colorectal Cancer. (PubMed, Int J Mol Sci)
    Immune checkpoint receptors (LAG3, CD27) connect via PPI intermediates to Ca2+ and K+ channels, targetable by relatlimab (FDA-approved) and varlilumab (Phase 2). This work maps previously unknown links between CRC driver genes and ion channel regulation, with the ataluren-RPS21-KCNQ2 axis ready for pharmacological testing.
    Journal • IO biomarker
    |
    LAG3 (Lymphocyte Activating 3) • CD27 (CD27 Molecule)
    |
    relatlimab (BMS-986016) • varlilumab (CDX 1127) • Translarna (ataluren)
    1m
    HERV-E TCR Transduced Autologous T Cells in People With Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P1, N=17, Active, not recruiting, National Heart, Lung, and Blood Institute (NHLBI) | Trial completion date: Mar 2026 --> Mar 2029
    Trial completion date
    |
    cyclophosphamide
    1m
    EBVision: A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases (clinicaltrials.gov)
    P2, N=190, Active, not recruiting, Pierre Fabre Medicament | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tab-cel (tabelecleucel)
    2ms
    NeoIRX: Pembrolizumab, IRX-2, and Chemotherapy in Triple Negative Breast Cancer (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Providence Health & Services | Trial completion date: Dec 2025 --> Dec 2026
    Trial completion date
    |
    Keytruda (pembrolizumab) • doxorubicin hydrochloride • cyclophosphamide • citoplurikin (IRX-2)
    2ms
    IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, City of Hope Medical Center | Trial completion date: Mar 2026 --> Mar 2027 | Trial primary completion date: Mar 2026 --> Mar 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • cyclophosphamide • citoplurikin (IRX-2)